BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berot...
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: GlobeNewswire
– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P – – ORLADEYO oral granules are currently under review with U.S. FDA for ages 2 to RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data demonstrating the early and negative psychosocial impact of hereditary angioedema (HAE) and resulting emergency department (ED) and hospital visits on pediatric patients and their caregivers, as well as new one-year data from the ongoing APeX-P clinical trial showing early and sustained reductions in monthly attack rates over one year in pediatric patients with HAE aged 2 to ® (berotralstat). The New Drug Application (NDA) for an oral granule formulation of once-daily ORLADEY
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]Yahoo! Finance
- BioCryst Receives Early Termination of HSR Waiting Period for Astria AcquisitionGlobeNewswire
- BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 11/3/25 - Beat
BCRX
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 144
- 12/3/25 - Form 8-K
- BCRX's page on the SEC website